TY - JOUR T1 - Change in glomerular filtration rate over time in the Oxford Renal Cohort Study: observational study JF - British Journal of General Practice JO - Br J Gen Pract SP - e261 LP - e268 DO - 10.3399/BJGP.2021.0477 VL - 72 IS - 717 AU - Jennifer A Hirst AU - Maarten W Taal AU - Simon DS Fraser AU - José M Ordóñez Mena AU - Chris A O’Callaghan AU - Richard J McManus AU - Clare J Taylor AU - Yaling Yang AU - Emma Ogburn AU - FD Richard Hobbs Y1 - 2022/04/01 UR - http://bjgp.org/content/72/717/e261.abstract N2 - Background Decline in kidney function can result in adverse health outcomes. The Oxford Renal Cohort Study has detailed baseline assessments from 884 participants ≥60 years of age.Aim To determine the proportion of participants with a decline in estimated glomerular filtration rate (eGFR), identify determinants of decline, and determine proportions with chronic kidney disease (CKD) remission.Design and setting Observational cohort study in UK primary care.Method Data were used from baseline and annual follow-up assessments to monitor change in kidney function. Rapid eGFR decline was defined as eGFR decrease >5 ml/min/1.73 m2/year, improvement as eGFR increase >5 ml/min/1.73 m2/year, and remission in those with CKD at baseline and eGFR >60 ml/min/1.73 m2 during follow-up. Cox proportional hazard models were used to identify factors associated with eGFR decline.Results There was a net decline in eGFR in the 884 participants over 5 years of follow-up. In 686 participants with >2 eGFR tests with a median follow-up of 2.1 years, 164 (24%) evidenced rapid GFR decline, 185 (27%) experienced eGFR improvement, and 82 of 394 (21%) meeting CKD stage 1–4 at baseline experienced remission. In the multivariable analysis, smoking status, higher systolic blood pressure, and being known to have CKD at cohort entry were associated with rapid GFR decline. Those with CKD stage 3 at baseline were less likely to exhibit GFR decline compared with normal kidney function.Conclusion This study established that 24% of people evidenced rapid GFR decline whereas 21% evidenced remission of CKD. People at risk of rapid GFR decline may benefit from closer monitoring and appropriate treatment to minimise risks of adverse outcomes, although only a small proportion meet the National Institute for Health and Care Excellence criteria for referral to secondary care. ER -